TORONTO, ON / ACCESSWIRE / May 3, 2021 / Noetic Foundry, an operating company building psychedelic biotechnology startups, is pleased to announce the appointment of Dr. Tim Piser as its Chief Scientific Officer. Dr. Piser has over 25 years of neuroscience drug discovery and development expertise at both large pharmaceutical and
Identifying and building breakthrough treatments in psychedelic medicine for the betterment of health and wellbeing.
The global cost of mental health issues is rising and will reach $6 trillion per year by 2030, with 12 billion working days lost per year due to mental illness. However, pharmaceutical industry R&D on mental health and central nervous system (CNS) disorders has fallen by 70% in the last 10 years.
Psychoactive molecules and their related compounds offer a truly ‘disruptive technology’ to treat many of society’s greatest unmet medical and mental health needs. Psychedelic medicine offers higher efficacy rates, minimal toxicity, lower treatment costs and customized solutions to those suffering from medical and mental health disorders.
An Operating Biotechnology Company Focused on Psychedelic Medicine
Noetic Foundry brings together the brightest people and most transformative solutions to assist in managing and solving mental health, addiction, and central nervous system ailments globally.
We identify and build breakthrough therapies, protocols, compounds, and technologies.
Psychedelic medicine and adjacent therapeutics will fundamentally change the pharmaceutical industry. Higher efficacy rates, minimal toxicity, lower treatment costs, and customized solutions present transformative modes of care and treatment for mental health ailments and beyond.
The psychedelic space is nascent, and is set to experience exponential growth in the coming decade as this class of medicines attract further institutional interest; notably from governments, researchers, and investors. We plan to be at the forefront of this renaissance, fostering development in white space.
We focus on high potential but underfunded segments of the emergent psychedelic value chain, as well as projects operating in adjacent fields such as CNS and broader mental health and wellbeing. Our focus is eclectic and ranges from novel synthetic methodologies, right through to innovative and personalized treatment modalities.
Join Noetic Foundry
We’re building a psychedelic biotech network that connects researchers and entrepreneurs, bringing together industry-leading cross-functional teams that can tackle some of society’s most pressing mental health and medical problems through psychedelic medicine.
If you’re interested in joining us—as an individual, research group, or nascent company—please get in touch via firstname.lastname@example.org.
Noetic Foundry has closed an oversubscribed round to fund its first group of biotechnology companies TORONTO, ON / March 30, 2021 / The Noetic team is pleased to announce that Noetic Foundry closed an oversubscribed round of financing earlier this year and is in the final stages of launching its first cohort
Meet The Team
Co-Founder (Interim CEO)
Managing Partner in the Noetic / Grey House Partners ecosystem of companies
12+ years of executive leadership in high-growth environments, (including driving >10X growth at Top Hat, Canada’s Startup of the Year) and as a consulting leader with McKinsey & Company
MBA from Harvard Business School, B.Com. from Queen’s University
Member of Young Presidents’ Organization
Dr. Tim Piser
Chief Scientific Officer
25+ years of experience in neuroscience drug discovery and drug development
Chief Scientific Officer of Cadent Therapeutics, acquired by Novartis in December 2020 for ~$800m USD
Former Global Product Director at AstraZeneca, overseeing neuroscience drug development programs
Ph.D. in Pharmacology from University of Minnesota-Twin Cities and B.Sc. In Biology from University of Delaware
Dr. Dave Rabin
Chief Innovation Officer
Co-Founder and CIO of Apollo Neuroscience
Board-certified psychiatrist, neuroscientist, tech entrepreneur & inventor
Clinical psychiatry practice and conducting research on the epigenetic regulation of trauma responses and recovery
MD and Ph.D. from Albany Medical College and psychiatric residency from Pittsburgh Medical Center
Dr. Richard Cheung
15+ years advising clients in the life sciences industry on intellectual property and regulatory matters at firms including Fasken, Ogilvy Renault (now Norton Rose Fulbright Canada), and Bereskin & Parr
Licensed pharmacist in the Province of Ontario with experience in community and hospital pharmacy
LL.B. from Western University
Ph.D. in Pharmaceutical Sciences (drug delivery) and B.Sc.Phm. (Pharmacy) from the University of Toronto
Registered Patent Agent and Trademark Agent in Canada
10+ years in international business leadership, including high-growth situations on all continents
Previously at McKinsey & Company in San Francisco, and as Chief Strategy Officer at HALO Diagnostics
M.Sc. (Tech.) in Management Science & Engineering from Stanford University; M.Sc. (Tech.) in Strategic Management and International Business from Aalto University
Dr. Urjita Shah
8+ years of neuroscience research experience (mental health disorders)
PhD in Pharmaceutical Sciences (Medicinal Chemistry- Glennon lab) and Postdoctoral Fellowship in Pharmacology and Chemical Biology (González-Maeso lab) from Virginia Commonwealth University, US
Bachelor of Pharmacy from Mumbai University, India
Dr. Sri Teja Mullapudi
Business Development Lead
Experienced in investment opportunity analysis in life sciences from TIAP (previously MaRS Innovation)
7+ years of research experience with 8 publications in peer-reviewed journals
Ph.D. (summa cum laude) in Biology from the Max Planck Society, Germany
M.Tech + B.Tech in Biotechnology (Minor in Chemistry) from Indian Institute of Technology Madras, India
Soccer player with Toronto City FC
Director of Finance
15+ years in Finance and Accounting, including responsibilities for controllership, finance & performance analysis, reporting, banking, insurance and tax operations
Most recently, Finance Controller and Canadian Financial Operations leader at Fusion Pharmaceuticals
B.Sc. in Accounting from the University of Benin and MBA from the University of Houston
Certified Public Accountant (CPA) and CFA Charterholder (Chartered Financial Analyst)
5+ years experience as a management consultant at Oliver Wyman in New York and San Francisco, including 1 year as Oliver Wyman’s Social Impact Practice Manager
BA Economics and MSc Commerce (Finance) from the University of Virginia
Currently pursuing an MA Psychology (focus in Neuroscience) at NYU
Dr. Mario de la Fuente
11+ years of experience in Neuroscience covering different stages of preclinical drug development
6+ years in Psychedelic Research; from the molecular to the human level and 25+ publications in neuropsychiatric research, medicinal chemistry and pharmacodynamics
PharmD and PhD in Drug Design (Complutense University of Madrid), Postdoctoral fellow in Neuropharmacology (Virginia Commonwealth University)
Involved in science communication in Psychedelic Science
Get the latest updates from Noetic Foundry
Get in touch